Advocates of the Make America Healthy Again agenda have expressed skepticism over President Donald Trump’s agreement with ...

For years, obesity rates in the US have gone in one direction: up. From the first year it was launched, Gallup’s National ...

Many doctors and patients came to believe the rise in obesity may be all but biologically inescapable, despite the grave ...

Even after Trump’s new deal, obesity drugs are still too expensive.

The president’s agreement with drug companies involves a range of prices, depending on dose, product and how you’re paying.

Medicare will cover semaglutide (Wegovy) and tirzepatide (Zepbound) for their weight management indications for people with ...

A small study helps explain why some people taking Wegovy and similar weight-loss drugs cut back on alcohol, offering insight ...

Certain blockbuster obesity drugs will be available for as little as $149 per month and more Medicare enrollees will have ...

Press Release President Donald J. Trump announced agreements with Eli Lilly and Novo Nordisk to reduce prices of available ...

Novo Nordisk, as well as Eli Lilly, would gain Medicare and Medicaid coverage for their blockbuster weight-loss drugs.

Trump announced new deals with Eli Lilly and Novo Nordisk to lower GLP-1 costs for Medicare, Medicaid, and cash-paying patients.